Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity

Ofer Zimmerman(Washington University in St. Louis), Michael Diamond(Washington University in St. Louis), Samantha Mackin(Washington University in St. Louis), Tiffany Dy(Washington University in St. Louis), Ali H. Ellebedy(Washington University in St. Louis), Laura A. VanBlargan(Washington University in St. Louis), Pritesh Desai(Washington University in St. Louis), Rachel M. Presti(Johns Hopkins University), Chieh-Yu Liang(Washington University in St. Louis), Alexa Michelle Altman Doss(Washington University in St. Louis), Rita E. Chen(Washington University in St. Louis), Daved H. Fremont(Washington University in St. Louis), Jackson S. Turner(Washington University in St. Louis), Zhen Ren(Washington University in St. Louis), Hannah G. Davis-Adams(Washington University in St. Louis), Peggy L. Kendall(Washington University in St. Louis), Caitlin C. O’Shaughnessy(Washington University in St. Louis), H. James Wedner(Washington University in St. Louis), Suzanne M. Scheaffer(Washington University in St. Louis), Lucas J. Adams(Washington University in St. Louis), Saravanan Raju(Washington University in St. Louis), C. Rigell(Washington University in St. Louis), Andrew L. Kau(Washington University in St. Louis), Tarisa L. Mantia(Washington University in St. Louis), Jennifer Monroy(Washington University in St. Louis), Baoling Ying(Washington University in St. Louis), Jane A. O’Halloran(St. Vincent's University Hospital)

JCI Insight

January 4, 2024

Cited by 10

|Nature|2012|2.4k

|Cell Metabolism|2016|1.5k

|Nature Microbiology|2020|1.1k

|Nature Medicine|2021|1k

|Nature Immunology|2020|997

Related Papers